SLC22A3 — Solute Carrier Family 22 Member 3 (OCT3)

SLC22A3 — Solute Carrier Family 22 Member 3 (OCT3)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC22A3 — Solute Carrier Family 22 Member 3 (OCT3)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC22A3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 22 Member 3 (OCT3)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6q27</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[6581](https://www.ncbi.nlm.nih.gov/gene/6581)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604349](https://www.omim.org/entry/604349)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000149402</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[O75727](https://www.uniprot.org/uniprot/O75727)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, depression, anxiety disorders</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Function</td>
</tr>
<tr>
<td class="label">rs2048327</td>
<td>Expression</td>
</tr>
<tr>
<td c

SLC22A3 — Solute Carrier Family 22 Member 3 (OCT3)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC22A3 — Solute Carrier Family 22 Member 3 (OCT3)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC22A3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 22 Member 3 (OCT3)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6q27</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[6581](https://www.ncbi.nlm.nih.gov/gene/6581)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604349](https://www.omim.org/entry/604349)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000149402</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[O75727](https://www.uniprot.org/uniprot/O75727)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, depression, anxiety disorders</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Function</td>
</tr>
<tr>
<td class="label">rs2048327</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">rs3088442</td>
<td>Coding (Ala427Ala)</td>
</tr>
<tr>
<td class="label">rs622342</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Ortholog</td>
</tr>
<tr>
<td class="label">Human</td>
<td>SLC22A3</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Slc22a3</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Slc22a3</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>slc22a3</td>
</tr>
</table>

{{.infobox .infobox-gene}}

Overview

Organic cation transporter 3 (OCT3), also known as the extraneuronal monoamine transporter (EMT), is a polyspecific transmembrane transporter encoded by the [SLC22A3](/genes/slc22a3) gene on chromosome 6q27[@koepsell2007]. OCT3 belongs to the solute carrier family 22 (SLC22) and mediates the Na⁺-independent transport of organic cations across cell membranes. Unlike neuronal transporters such as the dopamine transporter (DAT, encoded by [SLC6A3](/genes/slc6a3)) that primarily clear neurotransmitters from the synaptic cleft, OCT3 operates in the extraneuronal space to regulate ambient monoamine levels[@gasser2008].

OCT3 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration and neuropsychiatric disorders.

Gene Structure and Protein

The [SLC22A3](/genes/slc22a3) gene spans approximately 32 kb and consists of 11 exons. It encodes a 556-amino acid protein with 12 transmembrane domains (TMDs), characteristic of the major facilitator superfamily. The protein localizes to the plasma membrane and exhibits broad substrate specificity, accepting cationic neurotransmitters, drugs, and endogenous metabolites[@koepsell2007].

Key structural features include:

• N-glycosylation sites at the extracellular loops (Asn52, Asn58, Asn64)
• PKC phosphorylation sites regulating trafficking and activity
• C-terminal PDZ-binding motif for protein-protein interactions

Tissue Expression

OCT3 is expressed in multiple tissues throughout the body:

In the brain, OCT3 is expressed in:

• Astrocytes — the primary cellular source in CNS
• Neurons — particularly in cortex and hippocampus
• Endothelial cells — of the blood-brain barrier
• Microglia — emerging evidence suggests immune modulatory roles

Molecular Function

Monoamine Transport

OCT3 transports the following monoamine neurotransmitters:

• Dopamine — the primary substrate
• Norepinephrine (noradrenaline)
• Serotonin (5-HT)
• Histamine

• Low affinity (Km: 10-100 μM)
• High capacity — enables bulk clearance
• Broad specificity — accepts diverse substrates

Glucocorticoid Regulation

A unique feature of OCT3 is its regulation by glucocorticoids. Acute stress elevates corticosterone (in rodents) or cortisol (in humans), which rapidly (within minutes) upregulates OCT3 activity through non-genomic mechanisms[@bacher2018]. This creates a stress-responsive clearance pathway for monoamines, linking psychological stress to neurotransmitter dynamics.

The molecular pathway involves:

Blood-Brain Barrier Function

OCT3 plays a crucial role at the blood-brain barrier (BBB), where it contributes to the bidirectional transport of monoamines and drugs between the peripheral circulation and the central nervous system[@noll2020]. Unlike the BBB's tight junction barriers that restrict paracellular diffusion, OCT3-mediated transport provides a regulated gateway for specific substrates:

• Efflux function: OCT3 on brain endothelial cells can transport monoamines from the brain back to the blood, contributing to the clearance of excess neurotransmitters
• Influx function: The transporter can also bring in certain drugs and metabolites from the periphery
• Protective role: By clearing potentially neurotoxic monoamine metabolites from the brain interstitial fluid, OCT3 helps maintain CNS homeostasis

Neuroinflammation Modulation

Recent research has revealed that OCT3 participates in neuroinflammatory processes that are central to neurodegenerative diseases[@zhang2024]:

• Cytokine regulation: OCT3 can influence the expression and release of pro-inflammatory cytokines from astrocytes and microglia
• Monoamine-immune interface: By modulating extracellular monoamine levels, OCT3 indirectly affects immune cell function, as monoamines serve as signaling molecules in the immune system
• Glucocorticoid-immune crosstalk: The stress-responsive nature of OCT3 links psychological stress (via glucocorticoids) to neuroimmune responses

Circadian Rhythm Regulation

OCT3 exhibits diurnal variation in its expression and activity, contributing to the circadian regulation of monoaminergic neurotransmission:

• Time-of-day expression: OCT3 mRNA and protein levels show circadian oscillations in certain brain regions
• Monoamine clearance: The capacity for monoamine clearance varies across the circadian cycle, affecting neurotransmitter turnover
• Sleep-wake regulation: OCT3 function influences sleep architecture and arousal states through modulation of monoamine levels

Disease Associations

Alzheimer's Disease

OCT3 alterations have been implicated in Alzheimer's disease through several mechanisms:

Monoamine dysregulation hypothesis: AD is associated with progressive monoamine deficiency, particularly in the noradrenergic locus coeruleus system. OCT3 may represent a compensatory mechanism to clear accumulating extracellular monoamines that become neurotoxic at high concentrations.

Oxidative stress: Dopamine oxidation produces reactive oxygen species (ROS). Impaired OCT3 function may lead to increased extracellular dopamine, promoting oxidative damage to neurons—a hallmark of AD pathology.

Glucocorticoid toxicity: Chronic stress and elevated cortisol are risk factors for AD. OCT3 dysregulation may contribute to HPA axis dysregulation and cortisol-mediated neurotoxicity.

Neuropathological Findings

Post-mortem studies of AD brains have revealed alterations in [SLC22A3](/genes/slc22a3) expression[@wang2022]:

• Decreased OCT3 mRNA levels in the prefrontal cortex
• Altered protein localization in hippocampal regions
• Correlation between OCT3 expression and neurofibrillary tangle density

Therapeutic Implications

Targeting OCT3 in AD may provide therapeutic benefits:

• Monoamine modulation: Enhancing OCT3 function could help restore monoaminergic deficits
• Stress response: Modulating glucocorticoid-OCT3 interactions may reduce stress-induced neurotoxicity
• BBB protection: OCT3 modulators could protect BBB integrity

Parkinson's Disease

OCT3 plays significant roles in PD pathophysiology:

Dopamine homeostasis: OCT3 contributes to extraneuronal dopamine clearance. Genetic variants in [SLC22A3](/genes/slc22a3) have been associated with PD susceptibility, potentially altering dopamine metabolism in the substantia nigra.

L-DOPA response: OCT3 may influence the pharmacokinetics of L-DOPA, the primary PD treatment, by affecting its distribution and clearance.

Alpha-synuclein interaction: Emerging research suggests monoamine transporters may influence alpha-synuclein ([SNCA](/genes/snca)) aggregation through effects on dopamine metabolism and oxidative stress.

Experimental Models

Studies in PD models have demonstrated OCT3 involvement[@he2023]:

• In toxin-based PD models (MPTP, 6-OHDA), OCT3 expression is altered
• OCT3 knockout mice show increased vulnerability to dopaminergic toxins
• Genetic variants may modify age of onset in PD patients

Treatment Considerations

OCT3 influences PD therapeutics:

• L-DOPA pharmacokinetics: OCT3-mediated transport affects L-DOPA brain entry and clearance
• Dopamine agonists: Some agonists may compete with OCT3 substrates
• Neuroprotection: OCT3 modulators could potentially protect remaining dopaminergic neurons

Depression and Anxiety

OCT3 is strongly implicated in mood disorders:

OCT3 knockout mice exhibit decreased anxiety-like behavior, indicating a role in anxiety regulation[@vialou2009].

Genetic associations: Polymorphisms in [SLC22A3](/genes/slc22a3) have been linked to major depressive disorder and anxiety disorders[@chen2004].

Stress response: Dysregulated OCT3 function may contribute to HPA axis dysfunction, a core feature of depression.

Other Neurological Conditions

• Attention deficit hyperactivity disorder (ADHD)
• Bipolar disorder
• Schizophrenia — particularly negative symptoms
• Migraine — due to histamine clearance

Genetic Variants

Common Polymorphisms

Several functional polymorphisms in [SLC22A3](/genes/slc22a3) have been characterized:

Disease-Associated Variants

Genome-wide association studies (GWAS) have identified [SLC22A3](/genes/slc22a3) variants in:

• [Parkinson's disease](/diseases/parkinsons-disease) Major depressive disorder
• Type 2 diabetes (affecting cardiac monoamine handling)

Pharmacogenomics

OCT3 polymorphisms significantly influence drug response[@wu2022]:

Psychotropic drugs:

• SSRIs: Variable OCT3 inhibition affects treatment response
• Tricyclic antidepressants: OCT3-mediated transport influences efficacy
• Atypical antipsychotics: OCT3 contributes to drug distribution

• L-DOPA: OCT3 affects brain penetration and response duration
• Dopamine agonists: Transport interactions influence bioavailability

• Pharmacogenetic testing for [SLC22A3](/genes/slc22a3) variants may guide drug selection
• Personalized dosing based on OCT3 genotype
• Drug-drug interaction considerations in polypharmacy

Pharmacological Relevance

Drug Transport

OCT3 transports numerous drugs and toxins:

Substrates:

• Metformin
• Cimetidine
• Tetraethylammonium (TEA)
• 1-methyl-4-phenylpyridinium (MPP⁺)

• Decynium-22 (classic inhibitor)
• Corticosteroids (endogenous)
• Various antidepressants

Therapeutic Implications

Modulating OCT3 activity represents a potential therapeutic strategy:

• Antidepressants — some SSRIs inhibit OCT3
• Parkinson's drugs — OCT3 modulators may enhance L-DOPA efficacy
• Stress-related disorders — OCT3 enhancers could reduce anxiety

Interactions and Pathways

OCT3 interacts with several proteins and pathways:

Protein Interactions

• [SNCA](/genes/snca) — alpha-synuclein (possible)
• DAT ([SLC6A3](/genes/slc6a3)) — complementary function
• NET ([SLC6A2](/genes/slc6a2)) — norepinephrine transporter
• SLC22A2 ([OCT2](/genes/slc22a2)) — paralog with overlapping substrates

Pathway Membership

• Monoamine metabolism — catecholamine degradation
• Glucocorticoid signaling — stress response
• Drug metabolism — pharmacokinetics
• Oxidative stress response — neuroprotection

Research Directions

Outstanding Questions

Emerging Areas

• Neuroinflammation: OCT3 may modulate microglial monoamine handling
• Blood-brain barrier: OCT3 role in drug penetration
• Circadian rhythms: Diurnal monoamine regulation

Clinical Presentation

Depression Phenotypes

OCT3 dysfunction may manifest in specific depression phenotypes:

Atypical depression: Characterized by mood reactivity (mood improves with positive events), increased appetite, and hypersomnia. Altered monoamine clearance could contribute to the baseline elevated mood observed in this subtype.

Melancholic depression: Features include anhedonia, psychomotor retardation, and diurnal variation. OCT3 may influence the monoamine fluctuations underlying these symptoms.

Cortisol rhythm alterations: Many depressed patients show flattened cortisol diurnal rhythm. OCT3, being glucocorticoid-regulated, may contribute to this dysregulation.

Anxiety Disorders

Generalized anxiety disorder (GAD): OCT3 variants may influence worry and arousal through effects on norepinephrine clearance in prefrontal cortex.

Panic disorder: Altered monoamine clearance could affect the fight-or-flight response circuitry.

Social anxiety disorder: OCT3 in the amygdala and prefrontal cortex may modulate fear responses.

Parkinson's Disease Clinical Features

Motor fluctuations: OCT3 may influence L-DOPA pharmacokinetics, affecting "on-off" fluctuations.

Non-motor symptoms: Depression, anxiety, and fatigue in PD may involve OCT3 dysfunction.

Neuroimaging findings: PET studies using OCT3 substrates could reveal transporter availability in PD brains.

Comparative Biology

Evolutionary Conservation

OCT3 is conserved across mammals:

Species Differences

• Rodent OCT3 shows higher basal activity
• Glucocorticoid regulation differs between rodents and humans
• Regional brain expression patterns vary

Diagnostic and Therapeutic Considerations

Biomarker Potential

OCT3 as a biomarker:

• PET ligands: Developing selective OCT3 ligands for neuroimaging
• Blood markers: Peripheral OCT3 expression may correlate with CNS function
• Pharmacogenomics: OCT3 genotype predicting drug response

Therapeutic Modulation

Current and potential therapeutic approaches:

Selective serotonin reuptake inhibitors (SSRIs): Some SSRIs inhibit OCT3, contributing to their mechanism.

Monoamine oxidase inhibitors (MAOIs): Combined with OCT3 function for enhanced monoamine levels.

Novel drug development: Selective OCT3 modulators are in development.

Research Methods

Studying OCT3 Function

In vitro approaches:

• Xenopus oocyte expression
• HEK293 cell transfection
• Primary astrocyte culture

• Knockout mice
• Conditional knockouts
• Viral vector delivery

• Genetic association studies
• Post-mortem brain analysis
• PET neuroimaging

Biomarker Development

OCT3 as a biomarker for neurodegenerative diseases:

Diagnostic potential:

• Blood OCT3 expression as peripheral marker
• Brain imaging with selective ligands
• Genetic variant analysis for risk prediction

• Longitudinal OCT3 expression changes
• Correlation with disease progression
• Treatment response biomarkers

Future Directions

Research on OCT3 continues to evolve:

Gene therapy approaches: Viral vector-mediated OCT3 overexpression for neuroprotection

Stem cell models: iPSC-derived neurons from patients with [SLC22A3](/genes/slc22a3) variants

Novel ligands: Development of PET tracers for OCT3 imaging in vivo

Systems biology: Integration of OCT3 data into monoamine network models

Key Publications

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Pathway](/mechanisms/dopamine-biosynthesis)
• [Monoamine Oxidases](/proteins/mao-a-protein)
• [SLC6A3 (DAT)](/genes/slc6a3)
• [SLC6A2 (NET](/genes/slc6a2)

References

[@gasser2008]: Gasser et al. [Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice](https://pubmed.ncbi.nlm.nih.gov/18513366/). Neuropsychopharmacology. 2008;33(5):1154-1168.

[@vialou2009]: Vialou et al. [Decreased anxiety in mice lacking the organic cation transporter 3](https://pubmed.ncbi.nlm.nih.gov/19280114/). Neuropsychopharmacology. 2009;34(2):424-435.

[@bacher2018]: Bacher et al. [Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior](https://pubmed.ncbi.nlm.nih.gov/29738736/). Neuropsychopharmacology. 2018;43(8):1711-1720.

[@bacher2021]: Bacher et al. [General Overview of Organic Cation Transporters in Brain](https://pubmed.ncbi.nlm.nih.gov/33782773/). Handb Exp Pharmacol. 2021;257:39-54.

[@koepsell2007]: Koepsell et al. [Polyspecific organic cation transporters: structure, function, physiological roles](https://pubmed.ncbi.nlm.nih.gov/17473959/). J Membr Biol. 2007;213(2-3):69-77.

[@chen2004]: Chen et al. [OCT3 polymorphisms and the risk of psychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/15525984/). Neuropsychopharmacology. 2004;29(11):1952-1955.

[@zwart2001]: Zwart et al. [Polymorphisms in human organic cation transporter 3: implications for drug transport and drug-induced toxicity](https://pubmed.ncbi.nlm.nih.gov/11760644/). Pharmacogenomics. 2001;2(3):151-158.

[@wagner2009]: Wagner et al. [Organic cation transporters in the liver and kidney](https://pubmed.ncbi.nlm.nih.gov/19299564/). J Pharmacol Exp Ther. 2009;331(2):651-660.

[@nies2016]: Nies et al. [Organic cation transporters in drug disposition and hepatotoxicity](https://pubmed.ncbi.nlm.nih.gov/27885687/). Handb Exp Pharmacol. 2016;236:195-224.

[@berk2023]: Berk et al. [OCT3 function in stress-related disorders](https://pubmed.ncbi.nlm.nih.gov/36753492/). Psychopharmacology. 2023;240(3):421-435.

[@kretchmer2011]: Kretchmer et al. [Organic cation transporters in psychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/21777145/). J Neurochem. 2011;119(1):1-12.

[@caille2019]: Caille et al. [Glucocorticoid regulation of monoamine transporters](https://pubmed.ncbi.nlm.nih.gov/31028745/). Neuropharmacology. 2019;148:128-138.

[@segerer2019]: Segerer et al. [OCT3 expression in human brain](https://pubmed.ncbi.nlm.nih.gov/31190214/). J Neural Transm. 2019;126(8):1069-1079.

[@haasser2005]: Haasser et al. [Altered dopamine turnover in OCT3 knockout mice](https://pubmed.ncbi.nlm.nih.gov/15854623/). Synapse. 2005;58(4):258-265.

[@kurt2021]: Kurt B, et al. [Organic cation transporter 3 in neuropsychopharmacology](https://pubmed.ncbi.nlm.nih.gov/33448123/). Neuropsychopharmacology. 2021;46(12):2141-2153.

[@noll2020]: Noll C, et al. [OCT3 and the blood-brain barrier](https://pubmed.ncbi.nlm.nih.gov/31782721/). J Cereb Blood Flow Metab. 2020;40(12):2365-2378.

[@wang2022]: Wang L, et al. [SLC22A3 in Alzheimer's disease neuropathology](https://pubmed.ncbi.nlm.nih.gov/35115234/). Acta Neuropathol. 2022;143(2):177-195.

[@he2023]: He J, et al. [Monoamine transporter dysfunction in PD models](https://pubmed.ncbi.nlm.nih.gov/36455512/). Neurobiol Dis. 2023;175:105897.

[@zhang2024]: Zhang Y, et al. [OCT3 in stress-induced neuropsychiatric disorders](https://pubmed.ncbi.nlm.nih.gov/37856621/). Mol Psychiatry. 2024;29(1):56-68.

[@wu2022]: Wu X, et al. [Polymorphisms of SLC22A3 and drug response](https://pubmed.ncbi.nlm.nih.gov/35142345/). Pharmacogenomics. 2022;23(2):87-101.

External Links

• [NCBI Gene: 6581](https://www.ncbi.nlm.nih.gov/gene/6581)
• [Ensembl: ENSG00000149402](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149402)
• [UniProt: O75727](https://www.uniprot.org/uniprot/O75727)